TaiRx Company Description

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.

The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial.

Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.

The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs.

The company was founded in 2011 and is based in Taipei, Taiwan.

TaiRx, Inc.

Country	Taiwan
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	29
CEO	Du-Shieng Chien

Contact Details

Address: No. 66, San-Chung Road Taipei, 11502 Taiwan
Phone	886 2 2653 5007
Website	trx.com.tw

Stock Details

Ticker Symbol	6580
Exchange	Taipei Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006580004
SIC Code	2836

Key Executives

Name	Position
Dr. Du-Shieng Chien Ph.D.	Co-Founder, President, Chief Executive Officer and Director
Huang Shiqi M.A.	Chief Financial Officer and Accounting Supervisor
Dr. Yi-Wen Chu Ph.D.	Senior Vice President and Director